'0':
  level: 1
  section_number: ''
  section_title: Title Sheet
  file: m11_title_sheet.html
'1':
  level: 1
  section_number: '1'
  section_title: Protocol Summary
  header_only: false
  elements: []
  text: ''
'1.1':
  level: 2
  section_number: '1.1'
  section_title: Protocol Synopsis
  header_only: false
  elements: []
  text: ''
'1.1.1':
  level: 3
  section_number: 1.1.1
  section_title: Primary and Secondary Objectives and Endpoints
  header_only: false
  elements: []
  text: ''
'1.1.2':
  level: 3
  section_number: 1.1.2
  section_title: Overall Design
  header_only: false
  elements: []
  text: ''
'1.2':
  level: 2
  section_number: '1.2'
  section_title: Trial Schema
  header_only: false
  elements: []
  text: ''
'1.3':
  level: 2
  section_number: '1.3'
  section_title: Schedule of Activities
  header_only: false
  elements: []
  text: ''
'2':
  level: 1
  section_number: '2'
  section_title: Introduction
  header_only: false
  elements: []
  text: ''
'2.1':
  level: 2
  section_number: '2.1'
  section_title: Purpose of Trial
  header_only: false
  elements: []
  text: ''
'2.2':
  level: 2
  section_number: '2.2'
  section_title: Summary of Benefits and Risks
  header_only: false
  elements: []
  text: ''
2.2.1:
  level: 3
  section_number: 2.2.1
  section_title: Benefit Summary
  header_only: false
  elements: []
  text: ''
2.2.2:
  level: 3
  section_number: 2.2.2
  section_title: Risk Summary and Mitigation Strategy
  header_only: false
  elements: []
  text: ''
2.2.3:
  level: 3
  section_number: 2.2.3
  section_title: Overall Benefit:Risk Conclusion
  header_only: false
  elements: []
  text: ''
'3':
  level: 1
  section_number: '3'
  section_title: Trial Objectives, Endpoints and Estimands
  header_only: false
  elements: []
  text: ''
'3.1':
  level: 2
  section_number: '3.1'
  section_title: '{Primary/Secondary/Exploratory} Objective + Associated Endpoint
    {and Estimand}'
  header_only: false
  elements: []
  text: ''
3.1.1:
  level: 3
  section_number: 3.1.1
  section_title: '{Primary/Secondary/Exploratory} Estimand'
  header_only: false
  elements: []
  text: ''
'4':
  level: 1
  section_number: '4'
  section_title: Trial Design
  header_only: false
  elements: []
  text: ''
'4.1':
  level: 2
  section_number: '4.1'
  section_title: Description of Trial Design
  header_only: false
  elements: []
  text: ''
4.1.1:
  level: 3
  section_number: 4.1.1
  section_title: Stakeholder Input into Design
  header_only: false
  elements: []
  text: ''
'4.2':
  level: 2
  section_number: '4.2'
  section_title: Rationale for Trial Design
  header_only: false
  elements: []
  text: ''
4.2.1:
  level: 3
  section_number: 4.2.1
  section_title: Rationale for Intervention Model
  header_only: false
  elements: []
  text: ''
4.2.2:
  level: 3
  section_number: 4.2.2
  section_title: Rationale for Duration
  header_only: false
  elements: []
  text: ''
4.2.3:
  level: 3
  section_number: 4.2.3
  section_title: Rationale for Endpoints
  header_only: false
  elements: []
  text: ''
4.2.4:
  level: 3
  section_number: 4.2.4
  section_title: Rationale for Interim Analysis
  header_only: false
  elements: []
  text: ''
4.2.5:
  level: 3
  section_number: 4.2.5
  section_title: Rationale for Comparator
  header_only: false
  elements: []
  text: ''
4.2.6:
  level: 3
  section_number: 4.2.6
  section_title: Rationale for Adaptive or Novel Trial Design
  header_only: false
  elements: []
  text: ''
4.2.7:
  level: 3
  section_number: 4.2.7
  section_title: Rationale for Other Trial Design Aspects
  header_only: false
  elements: []
  text: ''
'4.3':
  level: 2
  section_number: '4.3'
  section_title: Trial Stopping Rules
  header_only: false
  elements: []
  text: ''
4.3.1:
  level: 3
  section_number: 4.3.1
  section_title: '{Temporary Trial Halt}'
  header_only: false
  elements: []
  text: ''
'4.4':
  level: 2
  section_number: '4.4'
  section_title: Start of Trial and End of Trial
  header_only: false
  elements: []
  text: ''
'4.5':
  level: 2
  section_number: '4.5'
  section_title: Access to Trial Intervention After End of Trial
  header_only: false
  elements: []
  text: ''
'5':
  level: 1
  section_number: '5'
  section_title: Trial Population
  header_only: false
  elements: []
  text: ''
'5.1':
  level: 2
  section_number: '5.1'
  section_title: Description of Trial Population and Rationale
  header_only: false
  elements: []
  text: ''
'5.2':
  level: 2
  section_number: '5.2'
  section_title: Inclusion Criteria
  header_only: false
  elements: []
  text: ''
'5.3':
  level: 2
  section_number: '5.3'
  section_title: Exclusion Criteria
  header_only: false
  elements: []
  text: ''
'5.4':
  level: 2
  section_number: '5.4'
  section_title: Contraception
  header_only: false
  elements: []
  text: ''
'5.5':
  level: 2
  section_number: '5.5'
  section_title: Lifestyle Restrictions
  header_only: false
  elements: []
  text: ''
5.5.1:
  level: 3
  section_number: 5.5.1
  section_title: Meals and Dietary Restrictions
  header_only: false
  elements: []
  text: ''
5.5.2:
  level: 3
  section_number: 5.5.2
  section_title: Caffeine, Alcohol, Tobacco, and Other Restrictions
  header_only: false
  elements: []
  text: ''
5.5.3:
  level: 3
  section_number: 5.5.3
  section_title: Physical Activity Restrictions
  header_only: false
  elements: []
  text: ''
5.5.4:
  level: 3
  section_number: 5.5.4
  section_title: Other Activity Restrictions
  header_only: false
  elements: []
  text: ''
'5.6':
  level: 2
  section_number: '5.6'
  section_title: Screen Failure and Rescreening
  header_only: false
  elements: []
  text: ''
'6':
  level: 1
  section_number: '6'
  section_title: Trial Intervention And Concomitant Therapy
  header_only: false
  elements: []
  text: ''
'6.1':
  level: 2
  section_number: '6.1'
  section_title: Description of Investigational Trial Intervention
  header_only: false
  elements: []
  text: ''
'6.2':
  level: 2
  section_number: '6.2'
  section_title: Rationale for Investigational Trial Intervention Dose and Regimen
  header_only: false
  elements: []
  text: ''
'6.3':
  level: 2
  section_number: '6.3'
  section_title: Investigational Trial Intervention Administration
  header_only: false
  elements: []
  text: ''
6.3.1:
  level: 3
  section_number: 6.3.1
  section_title: Investigational Trial Intervention Dose Modification
  header_only: false
  elements: []
  text: ''
'6.4':
  level: 2
  section_number: '6.4'
  section_title: Management of Investigational Trial Intervention Overdose
  header_only: false
  elements: []
  text: ''
'6.5':
  level: 2
  section_number: '6.5'
  section_title: Preparation, Storage, Handling and Accountability of Investigational
    Trial Intervention(s)
  header_only: false
  elements: []
  text: ''
6.5.1:
  level: 3
  section_number: 6.5.1
  section_title: Preparation of Investigational Trial Intervention(s)
  header_only: false
  elements: []
  text: ''
6.5.2:
  level: 3
  section_number: 6.5.2
  section_title: Storage and Handling of Investigational Trial Intervention
  header_only: false
  elements: []
  text: ''
6.5.3:
  level: 3
  section_number: 6.5.3
  section_title: Accountability of Investigational Trial Intervention
  header_only: false
  elements: []
  text: ''
'6.6':
  level: 2
  section_number: '6.6'
  section_title: Investigational Trial Intervention Assignment, Randomisation and
    Blinding
  header_only: false
  elements: []
  text: ''
6.6.1:
  level: 3
  section_number: 6.6.1
  section_title: Participant Assignment to Investigational Trial Intervention
  header_only: false
  elements: []
  text: ''
6.6.2:
  level: 3
  section_number: 6.6.2
  section_title: Randomisation
  header_only: false
  elements: []
  text: ''
6.6.3:
  level: 3
  section_number: 6.6.3
  section_title: '{Blinding}'
  header_only: false
  elements: []
  text: ''
6.6.4:
  level: 3
  section_number: 6.6.4
  section_title: '{Emergency Unblinding at the Site}'
  header_only: false
  elements: []
  text: ''
'6.7':
  level: 2
  section_number: '6.7'
  section_title: Investigational Trial Intervention Compliance
  header_only: false
  elements: []
  text: ''
'6.8':
  level: 2
  section_number: '6.8'
  section_title: Description of Non-Investigational Trial Intervention(s)
  header_only: false
  elements: []
  text: ''
6.8.1:
  level: 3
  section_number: 6.8.1
  section_title: '{Background Intervention}'
  header_only: false
  elements: []
  text: ''
6.8.2:
  level: 3
  section_number: 6.8.2
  section_title: '{Rescue Therapy}'
  header_only: false
  elements: []
  text: ''
6.8.3:
  level: 3
  section_number: 6.8.3
  section_title: '{Other Therapy}'
  header_only: false
  elements: []
  text: ''
'6.9':
  level: 2
  section_number: '6.9'
  section_title: Concomitant Therapy
  header_only: false
  elements: []
  text: ''
6.9.1:
  level: 3
  section_number: 6.9.1
  section_title: '{Prohibited Concomitant Therapy}'
  header_only: false
  elements: []
  text: ''
6.9.2:
  level: 3
  section_number: 6.9.2
  section_title: '{Permitted Concomitant Therapy}'
  header_only: false
  elements: []
  text: ''
'7':
  level: 1
  section_number: '7'
  section_title: Participant Discontinuation of Trial Intervention and Withdrawal
    From trial
  header_only: false
  elements: []
  text: ''
'7.1':
  level: 2
  section_number: '7.1'
  section_title: Discontinuation of Trial Intervention for Individual Participants
  header_only: false
  elements: []
  text: ''
7.1.1:
  level: 3
  section_number: 7.1.1
  section_title: Permanent Discontinuation of Trial Intervention
  header_only: false
  elements: []
  text: ''
7.1.2:
  level: 3
  section_number: 7.1.2
  section_title: Temporary Discontinuation of Trial Intervention
  header_only: false
  elements: []
  text: ''
7.1.3:
  level: 3
  section_number: 7.1.3
  section_title: Rechallenge
  header_only: false
  elements: []
  text: ''
'7.2':
  level: 2
  section_number: '7.2'
  section_title: Withdrawal from the Trial
  header_only: false
  elements: []
  text: ''
'7.3':
  level: 2
  section_number: '7.3'
  section_title: Lost to Follow-Up
  header_only: false
  elements: []
  text: ''
'7.4':
  level: 2
  section_number: '7.4'
  section_title: Participant Stopping Rules
  header_only: false
  elements: []
  text: ''
'8':
  level: 1
  section_number: '8'
  section_title: Trial Assessments and Procedures
  header_only: false
  elements: []
  text: ''
'8.1':
  level: 2
  section_number: '8.1'
  section_title: Screening/Baseline Assessments and Procedures
  header_only: false
  elements: []
  text: ''
'8.2':
  level: 2
  section_number: '8.2'
  section_title: Efficacy Assessments and Procedures
  header_only: false
  elements: []
  text: ''
'8.3':
  level: 2
  section_number: '8.3'
  section_title: Safety Assessments and Procedures
  header_only: false
  elements: []
  text: ''
8.3.1:
  level: 3
  section_number: 8.3.1
  section_title: Physical Examination
  header_only: false
  elements: []
  text: ''
8.3.2:
  level: 3
  section_number: 8.3.2
  section_title: Vital Signs
  header_only: false
  elements: []
  text: ''
8.3.3:
  level: 3
  section_number: 8.3.3
  section_title: Electrocardiograms
  header_only: false
  elements: []
  text: ''
8.3.4:
  level: 3
  section_number: 8.3.4
  section_title: Clinical Laboratory Assessments
  header_only: false
  elements: []
  text: ''
8.3.5:
  level: 3
  section_number: 8.3.5
  section_title: Pregnancy Testing
  header_only: false
  elements: []
  text: ''
8.3.6:
  level: 3
  section_number: 8.3.6
  section_title: Suicidal Ideation and Behaviour Risk Monitoring
  header_only: false
  elements: []
  text: ''
'8.4':
  level: 2
  section_number: '8.4'
  section_title: Pharmacokinetics
  header_only: false
  elements: []
  text: ''
'8.5':
  level: 2
  section_number: '8.5'
  section_title: Genetic Testing
  header_only: false
  elements: []
  text: ''
'8.6':
  level: 2
  section_number: '8.6'
  section_title: Biomarkers
  header_only: false
  elements: []
  text: ''
'8.7':
  level: 2
  section_number: '8.7'
  section_title: Immunogenicity Assessments
  header_only: false
  elements: []
  text: ''
'8.8':
  level: 2
  section_number: '8.8'
  section_title: Medical Resource Utilisation and Health Economics
  header_only: false
  elements: []
  text: ''
'9':
  level: 1
  section_number: '9'
  section_title: Adverse Events, Serious Adverse Events, Product Complaints, Pregnancy
    and Postpartum Information
  header_only: false
  elements: []
  text: ''
'9.1':
  level: 2
  section_number: '9.1'
  section_title: Definitions
  header_only: false
  elements: []
  text: ''
9.1.1:
  level: 3
  section_number: 9.1.1
  section_title: Definitions of Adverse Events
  header_only: false
  elements: []
  text: ''
9.1.2:
  level: 3
  section_number: 9.1.2
  section_title: Definitions of Serious Adverse Events
  header_only: false
  elements: []
  text: ''
9.1.3:
  level: 3
  section_number: 9.1.3
  section_title: Definitions Related to Childbearing Potential
  header_only: false
  elements: []
  text: ''
9.1.4:
  level: 3
  section_number: 9.1.4
  section_title: '{Definition of Medical Device Product Complaints}'
  header_only: false
  elements: []
  text: ''
'9.2':
  level: 2
  section_number: '9.2'
  section_title: Timing and Mechanism for Collection and Reporting
  header_only: false
  elements: []
  text: ''
'9.3':
  level: 2
  section_number: '9.3'
  section_title: Identification, Recording and Follow-Up
  header_only: false
  elements: []
  text: ''
9.3.1:
  level: 3
  section_number: 9.3.1
  section_title: Identification
  header_only: false
  elements: []
  text: ''
9.3.2:
  level: 3
  section_number: 9.3.2
  section_title: Intensity
  header_only: false
  elements: []
  text: ''
9.3.3:
  level: 3
  section_number: 9.3.3
  section_title: Causality
  header_only: false
  elements: []
  text: ''
9.3.4:
  level: 3
  section_number: 9.3.4
  section_title: Follow-up
  header_only: false
  elements: []
  text: ''
'9.4':
  level: 2
  section_number: '9.4'
  section_title: Reporting
  header_only: false
  elements: []
  text: ''
9.4.1:
  level: 3
  section_number: 9.4.1
  section_title: Regulatory Reporting Requirements
  header_only: false
  elements: []
  text: ''
9.4.2:
  level: 3
  section_number: 9.4.2
  section_title: Adverse Events of Special Interest
  header_only: false
  elements: []
  text: ''
9.4.3:
  level: 3
  section_number: 9.4.3
  section_title: Disease-related Events or Outcomes Not Qualifying as AEs or SAEs
  header_only: false
  elements: []
  text: ''
'9.5':
  level: 2
  section_number: '9.5'
  section_title: Pregnancy and Postpartum Information
  header_only: false
  elements: []
  text: ''
9.5.1:
  level: 3
  section_number: 9.5.1
  section_title: '{Participants Who Become Pregnant During the Trial}'
  header_only: false
  elements: []
  text: ''
9.5.2:
  level: 3
  section_number: 9.5.2
  section_title: '{Participants Whose Partners Become Pregnant}'
  header_only: false
  elements: []
  text: ''
'10':
  level: 1
  section_number: '10'
  section_title: Statistical Considerations
  header_only: false
  elements: []
  text: ''
'10.1':
  level: 2
  section_number: '10.1'
  section_title: Analysis Sets
  header_only: false
  elements: []
  text: ''
'10.2':
  level: 2
  section_number: '10.2'
  section_title: Analyses Supporting Primary Objective(s)
  header_only: false
  elements: []
  text: ''
10.2.1:
  level: 3
  section_number: 10.2.1
  section_title: Statistical Model, Hypothesis, and Method of Analysis
  header_only: false
  elements: []
  text: ''
10.2.2:
  level: 3
  section_number: 10.2.2
  section_title: Handling of Intercurrent Events of Primary Estimand(s)
  header_only: false
  elements: []
  text: ''
10.2.3:
  level: 3
  section_number: 10.2.3
  section_title: Handling of Missing Data
  header_only: false
  elements: []
  text: ''
10.2.4:
  level: 3
  section_number: 10.2.4
  section_title: Sensitivity Analysis
  header_only: false
  elements: []
  text: ''
10.2.5:
  level: 3
  section_number: 10.2.5
  section_title: Supplementary Analysis
  header_only: false
  elements: []
  text: ''
'10.3':
  level: 2
  section_number: '10.3'
  section_title: Analysis Supporting Secondary Objective(s)
  header_only: false
  elements: []
  text: ''
'10.4':
  level: 2
  section_number: '10.4'
  section_title: Analysis of Exploratory Objective(s)
  header_only: false
  elements: []
  text: ''
'10.5':
  level: 2
  section_number: '10.5'
  section_title: Safety Analyses
  header_only: false
  elements: []
  text: ''
'10.6':
  level: 2
  section_number: '10.6'
  section_title: Other Analyses
  header_only: false
  elements: []
  text: ''
'10.7':
  level: 2
  section_number: '10.7'
  section_title: Interim Analyses
  header_only: false
  elements: []
  text: ''
'10.8':
  level: 2
  section_number: '10.8'
  section_title: Sample Size Determination
  header_only: false
  elements: []
  text: ''
'10.9':
  level: 2
  section_number: '10.9'
  section_title: Protocol Deviations
  header_only: false
  elements: []
  text: ''
'11':
  level: 1
  section_number: '11'
  section_title: 'General Considerations: Regulatory, Ethical, And trial Oversight'
  header_only: false
  elements: []
  text: ''
'11.1':
  level: 2
  section_number: '11.1'
  section_title: Regulatory and Ethical Considerations
  header_only: false
  elements: []
  text: ''
'11.2':
  level: 2
  section_number: '11.2'
  section_title: Trial Oversight
  header_only: false
  elements: []
  text: ''
11.2.1:
  level: 3
  section_number: 11.2.1
  section_title: Investigator Responsibilities
  header_only: false
  elements: []
  text: ''
11.2.2:
  level: 3
  section_number: 11.2.2
  section_title: Sponsor Responsibilities
  header_only: false
  elements: []
  text: ''
'11.3':
  level: 2
  section_number: '11.3'
  section_title: Committees
  header_only: false
  elements: []
  text: ''
'11.4':
  level: 2
  section_number: '11.4'
  section_title: Informed Consent Process
  header_only: false
  elements: []
  text: ''
11.4.1:
  level: 3
  section_number: 11.4.1
  section_title: Informed Consent for Rescreening
  header_only: false
  elements: []
  text: ''
11.4.2:
  level: 3
  section_number: 11.4.2
  section_title: Informed Consent for Use of Remaining Samples in Exploratory Research
  header_only: false
  elements: []
  text: ''
'11.5':
  level: 2
  section_number: '11.5'
  section_title: Insurance and Indemnity
  header_only: false
  elements: []
  text: ''
'11.6':
  level: 2
  section_number: '11.6'
  section_title: Early Site Closure
  header_only: false
  elements: []
  text: ''
'12':
  level: 1
  section_number: '12'
  section_title: 'General Considerations: Risk Management and Data Governance'
  header_only: false
  elements: []
  text: ''
'12.1':
  level: 2
  section_number: '12.1'
  section_title: Risk Management
  header_only: false
  elements: []
  text: ''
'12.2':
  level: 2
  section_number: '12.2'
  section_title: Data Governance
  header_only: false
  elements: []
  text: ''
'12.3':
  level: 2
  section_number: '12.3'
  section_title: Source Data
  header_only: false
  elements: []
  text: ''
'13':
  level: 1
  section_number: '13'
  section_title: 'Appendix: Definitions and Supporting Operational Details'
  header_only: false
  elements: []
  text: ''
'13.1':
  level: 2
  section_number: '13.1'
  section_title: Clinical Laboratory Tests
  header_only: false
  elements: []
  text: ''
'13.2':
  level: 2
  section_number: '13.2'
  section_title: Country/Region-Specific Differences
  header_only: false
  elements: []
  text: ''
'13.3':
  level: 2
  section_number: '13.3'
  section_title: Prior Protocol Amendment(s)
  header_only: false
  elements: []
  text: ''
'14':
  level: 1
  section_number: '14'
  section_title: 'Appendix:  Glossary of Terms and Abbreviations'
  header_only: false
  elements: []
  text: ''
'15':
  level: 1
  section_number: '15'
  section_title: 'Appendix:  References'
  header_only: false
  elements: []
  text: ''
